Rasoul Pourebrahim: New potential targets for preventing AML with p53 mutations

Rasoul Pourebrahim, Assistant Professor at MD Anderson Cancer Centre, shared on LinkedIn:

“Our paper was published in Cell Reports Medicine. .

We’re excited to share our latest publication, which features the development of new mouse models for studying mutant p53-driven Acute Myeloid Leukemia (AML).

Our research reveals a significant role for Mdm2 in influencing myeloid lineage commitment by affecting cholesterol biosynthesis, highlighting its importance in the transformation of myeloid HSCs to age-related AML.

These findings suggest new potential targets for preventing AML with p53 mutations, which are often resistant to existing treatments. By targeting these mechanisms at a preleukemic stage, we aim to prevent the development of AML in the context of p53 mutations, which are known for their resistance to current treatments.

Read more about our findings and the future implications for AML treatment here. Thank you to everyone involved for their hard work and dedication.”

Source: Rasoul Pourebrahim/LinkedIn